Saga Investments LLC
http://www.decode.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Saga Investments LLC
Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments
Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds.
Verve Not Ready To Pull Plug On Anti-PCSK9 Gene Editing Candidate
The company told Scrip that the sixth patient with elevated liver enzymes and low platelets recovered after hospital observation and oral steroids, and it may still continue VERVE-101’s development.
Conflicts Of Interest Delay Leqembi’s EU Approval
Eisai/Biogen’s Alzheimer’s drug has fallen foul of a recent court ruling over the handling of the European Medicines Agency’s experts' competing interests.
Leqembi’s EU Approval Process Delayed Over Advisory Group COI Considerations
The EU regulatory agency’s discussions for lecanemab’s approval are hit by a decision to annul advice from an advisory committee due to the implications of a Court of Justice ruling on the handling of experts' competing interests.
Company Information
- Other Names / Subsidiaries
-
- deCODE genetics ehf
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice